Cargando…

The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non–small cell lung cancer with sensitive EGFR mutations

BACKGROUND: Currently, the role of EGFR-TKIs as adjuvant therapy for stage I, especially IA NSCLC, after surgical resection remains unclear. We aimed to compare the effect of adjuvant EGFR-TKIs with observation in such patients by incorporating an established 14-gene molecular assay for risk stratif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yu, Lin, Yuechun, Fu, Wenhai, He, Qihua, Liang, Hengrui, Zhong, Ran, Cheng, Ran, Li, Bingliang, Wen, Yaokai, Wang, Huiting, Li, Jianfu, Li, Caichen, Xiong, Shan, Chen, Songan, Xiang, Jianxing, Mann, Michael J., He, Jianxing, Liang, Wenhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511786/ https://www.ncbi.nlm.nih.gov/pubmed/37745018 http://dx.doi.org/10.1016/j.eclinm.2023.102205

Ejemplares similares

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

The impact of postoperative EGFR-TKIs treatment on residual GGO lesions after resection for lung cancer
por: Cheng, Bo, et al.
Publicado: (2021)

Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients
por: Liang, Hengrui, et al.
Publicado: (2020)

Diagnostic Accuracy of Droplet Digital PCR and Amplification Refractory Mutation System PCR for Detecting EGFR Mutation in Cell-Free DNA of Lung Cancer: A Meta-Analysis
por: Li, Caichen, et al.
Publicado: (2020)

Dynamic monitoring serum tumor markers to predict molecular features of EGFR‐mutated lung cancer during targeted therapy
por: Chen, Zhuxing, et al.
Publicado: (2022)

Association between systemic lupus erythematosus and lung cancer: results from a pool of cohort studies and Mendelian randomization analysis
por: Peng, Haoxin, et al.
Publicado: (2020)

Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report
por: Chen, Zhuxing, et al.
Publicado: (2021)

A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer
por: Cui, Ran, et al.
Publicado: (2022)

Management for Residual Ground-Glass Opacity Lesions After Resection of Main Tumor in Multifocal Lung Cancer: A Case Report and Literature Review
por: Cheng, Bo, et al.
Publicado: (2021)

Prognostic and predictive impact of creatine kinase level in non-small cell lung cancer treated with tyrosine kinase inhibitors
por: Jiang, Yu, et al.
Publicado: (2021)

Aspirin and risk of different cancers: an umbrella meta-analysis
por: Jiang, Yu, et al.
Publicado: (2020)

Advances in lung cancer screening and early detection
por: Li, Caichen, et al.
Publicado: (2022)

Genetically predicted bipolar disorder is causally associated with an increased risk of breast cancer: a two-sample Mendelian randomization analysis
por: Peng, Haoxin, et al.
Publicado: (2021)

Univariable and Multivariable Two-Sample Mendelian Randomization Investigating the Effects of Leisure Sedentary Behaviors on the Risk of Lung Cancer
por: Peng, Haoxin, et al.
Publicado: (2021)

Adjuvant EGFR-TKIs-based therapy: are we ready?
por: Tam, Terence
Publicado: (2020)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Lung cancers and pulmonary nodules detected by computed tomography scan: a population-level analysis of screening cohorts
por: Li, Caichen, et al.
Publicado: (2021)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Inhaled corticosteroids and risk of lung cancer among chronic obstructive pulmonary disease patients: a comprehensive analysis of nine prospective cohorts
por: Ge, Fan, et al.
Publicado: (2021)

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma
por: Li, Qiwen, et al.
Publicado: (2021)

An annual review of the remarkable advances in lung cancer clinical research in 2019
por: Cheng, Bo, et al.
Publicado: (2020)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
por: Liang, Wenhua, et al.
Publicado: (2020)

EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
por: Milovancev, Aleksandar, et al.
Publicado: (2015)

Age at first birth and lung cancer: a two-sample Mendelian randomization study
por: Peng, Haoxin, et al.
Publicado: (2021)

Nomogram for predicting the survival rate of primary pulmonary mucoepidermoid carcinoma patients: a retrospective study based on SEER database
por: Lin, Guo, et al.
Publicado: (2021)

Cancer risk in heart or lung transplant recipients: A comprehensive analysis of 21 prospective cohorts
por: Ge, Fan, et al.
Publicado: (2020)

Combination therapy of first and third generation EGFR-TKIs for an advanced lung adenocarcinoma patient harboring EGFR mutations and amplification: a case report
por: Chen, Yongxing, et al.
Publicado: (2020)

Identifying optimal candidates for primary tumor resection among metastatic non-small cell lung cancer patients: a population-based predictive model
por: Liang, Hengrui, et al.
Publicado: (2021)

Novel evidence revealed genetic association between COVID-19 infection, severity and endometrial cancer
por: Wu, Xiangrong, et al.
Publicado: (2022)

Gout and susceptibility and severity of COVID-19: A bidirectional Mendelian randomization analysis
por: Peng, Haoxin, et al.
Publicado: (2022)

Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer
por: He, Miao, et al.
Publicado: (2023)

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
por: Yan, Han, et al.
Publicado: (2015)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
por: Lin, Chutong, et al.
Publicado: (2021)

High Incidence of EGFR Mutations in Pneumonic-Type Non-Small Cell Lung Cancer
por: Liu, Jun, et al.
Publicado: (2015)

Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report
por: Liang, Wenhua, et al.
Publicado: (2016)

Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers
por: Deng, Hongsheng, et al.
Publicado: (2022)

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
por: Wu, Xuan, et al.
Publicado: (2013)

“Major pathologic response” in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy
por: Deng, Hongsheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qqg10a4urtukbpn1le4nib754l